Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This investigational combination therapy, studied by the University of Chicago, consists of the systemic corticosteroid prednisolone and the antibiotic combination amoxicillin/clavulanate. It is being evaluated in a Phase 4 clinical trial (titled 'Steroids and Antibiotics for Childhood OSAS') for the treatment of mild obstructive sleep apnea syndrome (OSAS) in children aged 18 months to 12 years. The therapeutic rationale is to reduce the size of hypertrophic tonsils and adenoids by addressing both inflammation and potential chronic bacterial infection within the lymphoid tissues. By shrinking these tissues, the treatment aims to alleviate airway obstruction and improve sleep symptoms, potentially serving as a non-surgical alternative or adjunct to adenotonsillectomy, which is the standard first-line treatment for pediatric OSA.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on prednisolone + amoxicillin + clavulanate.